Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Short term Debt (2019 - 2025)

Vivos Therapeutics has reported Short term Debt over the past 4 years, most recently at $8.4 million for Q4 2025.

  • Quarterly Short term Debt changed N/A to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $8.4 million for FY2025, N/A changed from the prior year.
  • Short term Debt was $8.4 million for Q4 2025 at Vivos Therapeutics, up from $339000.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $8.4 million in Q4 2025 and troughed at $157000.0 in Q2 2025.